Co-Authors
This is a "connection" page, showing publications co-authored by GORDON B MILLS and AGDA KARINA B. ETEROVIC.
Connection Strength
1.318
-
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. Eur J Cancer. 2019 10; 120:54-64.
Score: 0.181
-
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. 2017 05 31; 9(392).
Score: 0.155
-
A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
Score: 0.134
-
Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem. 2015 Mar; 61(3):544-53.
Score: 0.132
-
The impact of tumor heterogeneity on patient treatment decisions. Clin Chem. 2013 Jan; 59(1):38-40.
Score: 0.057
-
Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502.
Score: 0.047
-
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget. 2019 Aug 27; 10(50):5254.
Score: 0.045
-
Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases. Breast Cancer Res Treat. 2019 Nov; 178(2):251-261.
Score: 0.045
-
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
Score: 0.045
-
Prospective Clinical Sequencing of Adult Glioma. Mol Cancer Ther. 2019 05; 18(5):991-1000.
Score: 0.044
-
Molecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer. 2018; 4:34.
Score: 0.043
-
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol. 2018; 2018.
Score: 0.041
-
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6468-6477.
Score: 0.040
-
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget. 2017 Jun 27; 8(26):41806-41814.
Score: 0.039
-
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
Score: 0.037
-
The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget. 2016 May 10; 7(19):27185-98.
Score: 0.036
-
Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2016; 11(3):e0151121.
Score: 0.036
-
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851.
Score: 0.034
-
Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015 Feb 20; 6(5):2604-14.
Score: 0.033
-
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget. 2014 Sep 30; 5(18):8544-57.
Score: 0.032
-
Bias from removing read duplication in ultra-deep sequencing experiments. Bioinformatics. 2014 04 15; 30(8):1073-1080.
Score: 0.031
-
Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol. 2014 Apr; 45(4):701-8.
Score: 0.030